BRPI0415299A - uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogas - Google Patents
uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogasInfo
- Publication number
- BRPI0415299A BRPI0415299A BRPI0415299-9A BRPI0415299A BRPI0415299A BR PI0415299 A BRPI0415299 A BR PI0415299A BR PI0415299 A BRPI0415299 A BR PI0415299A BR PI0415299 A BRPI0415299 A BR PI0415299A
- Authority
- BR
- Brazil
- Prior art keywords
- hepatotoxicity
- il1a
- genetic polymorphisms
- induced hepatotoxicity
- predict drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50897203P | 2003-10-06 | 2003-10-06 | |
| PCT/EP2004/011123 WO2005040415A1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms to predict drug-induced hepatotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0415299A true BRPI0415299A (pt) | 2006-12-26 |
Family
ID=34520003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415299-9A BRPI0415299A (pt) | 2003-10-06 | 2004-10-05 | uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070248955A1 (https=) |
| EP (1) | EP1673472B1 (https=) |
| JP (1) | JP4979382B2 (https=) |
| CN (1) | CN1882705A (https=) |
| AT (1) | ATE498021T1 (https=) |
| AU (1) | AU2004283234B2 (https=) |
| BR (1) | BRPI0415299A (https=) |
| CA (1) | CA2540760C (https=) |
| DE (1) | DE602004031352D1 (https=) |
| ES (1) | ES2361018T3 (https=) |
| MX (1) | MXPA06003827A (https=) |
| PL (1) | PL1673472T3 (https=) |
| PT (1) | PT1673472E (https=) |
| WO (1) | WO2005040415A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10262107B1 (en) * | 2013-03-15 | 2019-04-16 | Bao Tran | Pharmacogenetic drug interaction management system |
| CN108949947B (zh) * | 2017-05-25 | 2022-06-28 | 上海市预防医学研究院 | 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点 |
| CN116239665B (zh) * | 2023-03-10 | 2024-08-23 | 山东大学 | Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| CA2425363A1 (en) * | 2000-10-12 | 2003-04-10 | Fumihiko Sato | Benzimidazole compounds, process for producing the same and use thereof |
| GB0212648D0 (en) * | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
-
2004
- 2004-10-05 PT PT04765830T patent/PT1673472E/pt unknown
- 2004-10-05 JP JP2006530097A patent/JP4979382B2/ja not_active Expired - Fee Related
- 2004-10-05 DE DE602004031352T patent/DE602004031352D1/de not_active Expired - Lifetime
- 2004-10-05 WO PCT/EP2004/011123 patent/WO2005040415A1/en not_active Ceased
- 2004-10-05 BR BRPI0415299-9A patent/BRPI0415299A/pt not_active Application Discontinuation
- 2004-10-05 MX MXPA06003827A patent/MXPA06003827A/es active IP Right Grant
- 2004-10-05 ES ES04765830T patent/ES2361018T3/es not_active Expired - Lifetime
- 2004-10-05 PL PL04765830T patent/PL1673472T3/pl unknown
- 2004-10-05 EP EP04765830A patent/EP1673472B1/en not_active Expired - Lifetime
- 2004-10-05 CA CA2540760A patent/CA2540760C/en not_active Expired - Fee Related
- 2004-10-05 CN CNA2004800344189A patent/CN1882705A/zh active Pending
- 2004-10-05 AT AT04765830T patent/ATE498021T1/de active
- 2004-10-05 AU AU2004283234A patent/AU2004283234B2/en not_active Ceased
- 2004-10-05 US US10/574,768 patent/US20070248955A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1673472E (pt) | 2011-05-12 |
| AU2004283234A1 (en) | 2005-05-06 |
| ES2361018T3 (es) | 2011-06-13 |
| DE602004031352D1 (de) | 2011-03-24 |
| JP4979382B2 (ja) | 2012-07-18 |
| ATE498021T1 (de) | 2011-02-15 |
| AU2004283234B2 (en) | 2007-08-30 |
| PL1673472T3 (pl) | 2011-07-29 |
| CA2540760A1 (en) | 2005-05-06 |
| WO2005040415A1 (en) | 2005-05-06 |
| EP1673472B1 (en) | 2011-02-09 |
| US20070248955A1 (en) | 2007-10-25 |
| EP1673472A1 (en) | 2006-06-28 |
| JP2007512231A (ja) | 2007-05-17 |
| CA2540760C (en) | 2013-01-08 |
| MXPA06003827A (es) | 2006-06-14 |
| CN1882705A (zh) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200608961A (en) | Methods and reagents for the treatment of metabolic disorders | |
| MY143215A (en) | Multifocal lenses for pre-presbyopic individuals | |
| DK1316801T3 (da) | Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer | |
| CR9223A (es) | 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen | |
| CR10157A (es) | Compuestos químicos | |
| ATE527385T1 (de) | Mit tumoren assoziierte genetische variationen | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
| ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
| GT200800042A (es) | Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms | |
| DE602006017365D1 (de) | Zusammensetzungen für die identifizierung von adenoviren | |
| BRPI0519570A2 (pt) | mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos | |
| TR200003525T2 (tr) | Bipolar bozuklukların tedavisi için kombinasyon terapisi | |
| HN2008000360A (es) | Dispersiones amorfas solidas | |
| BRPI0514017A (pt) | indazóis úteis no tratamento de doenças cardiovasculares | |
| WO2005082341A3 (en) | NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF | |
| MX378733B (es) | Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus. | |
| CR10548A (es) | 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen | |
| CL2007002388A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas. | |
| GT200300046A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| BR0317284A (pt) | Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno | |
| BRPI0513297A (pt) | polipeptìdeo | |
| BRPI0414365A (pt) | composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes | |
| BRPI0415299A (pt) | uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogas | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DO PROTOCOLO ELETRONICO NO WBRJ 860140010156DE 30/01/2014. |